OT Staff Reports

Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy.” The findings are based on data from the Rhineland Study.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.

The study, conducted with Tufts Medical Center, represents a breakthrough showing that Microdose Array Print technology can provide similar benefits of non-preserved medications.

The latest announcement comes after the previously granted ODD for polihexanide in acanthamoeba keratitis by the FDA and EMA.

The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.

The company’s digital treatment device was proven to be non-inferior to eye patch treatment in a randomly assigned controlled study.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”

Bennie H. Jeng, MD, a corneal specialist, will assume his new role at Penn in July, succeeding Joan O’Brien, who will assume a new role as the inaugural director of the Penn Medicine Center for Ophthalmic Genetics in Complex Diseases.

Trial recruitment is enabled by the Foundation Fighting Blindness' patient registry, My Retina Tracker Registry, which includes gene

The clinical trial will evaluate the safety and tolerability of ADX-2191 in patients diagnosed with RP due to mutations of the rhodopsin gene, including the P23H gene mutation.

With a growing rate of childhood myopia, the company's MIRA-4 trial supports a broader RM label for Nyxol in pediatric patients from 3 to 11 years of age.

The company this week is rolling out its Clareon family of IOLs, including Monofocal, PanOptix and Vivity options.

The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.

A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

The companies note that the partnership will propel Ray Therapeutics’ lead optogenetics gene therapy to Phase 1-2 clinical trials.

The group is offering free sight-savings resources to employees and their employers.

The company expects to have topline proof of concept data by the end of the first quarter of the year.

TearSolutions Inc. is preparing to conduct two trials, one in a primary Sjögren’s Syndrome patient population and the second in a potentially less severe general dry eye population for the treatment of DED.

The organization uses its Eyes on Capitol Hill program to educate lawmakers and their staff on a variety of vision health issues, including vision health inequities, the need for improved vision surveillance, the impact of community eye health programs, and disparities in access to affordable eyecare services.

The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.

The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

The NGF0121 study will enroll 100 patients and will use Schirmer's test and the Symptom Assessment Questionnaire in Dry Eye questionnaire as its co-primary endpoints to measure improvement in signs and symptoms of dry eye over time.

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

According to data presented by Horizon Therapeutics at the North American Neuro-Ophthalmology Society annual meeting held this week in Austin, Texas, Uplizna treatment is linked to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer’s, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.